Parents Rejoice As An EpiPen Competitor Becomes Available at Much Lower Cost

Allergic reactions are no joke, and it doesn't help that Mylan's EpiPen has spiked the price by 400 percent. Fortunately, privately held drugmaker Kaleo announced Wednesday plans for a U.S. relaunch of its epinephrine auto-injector in early 2017. EpiPen's rival, Auvi-Q, will be reintroduced at a "very, very low" cost to patients, said Kaleo CEO Spencer Williamson.…